Early Study of JLM019 Injection for Advanced Cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This is an early-stage trial testing a new cancer treatment called JLM019 in patients with advanced solid tumors or lymphomas that haven't responded to other treatments. The study aims to find the right dose and see how well the drug works and how patients tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with confirmed advanced cancer (solid tumor or lymphoma) that has measurable disease on imaging
- Your cancer must not have spread to the brain, or if it has, it must have been treated and stable for at least 8 weeks
- You must be in good overall health (ECOG score 0–1) with life expectancy of at least 3 months and normal blood counts, kidney, liver, and heart function
- You must provide a tumor tissue sample (either archived or a fresh biopsy) for testing before starting the drug
- You cannot have received certain cancer treatments in the past 2–4 weeks (chemotherapy, targeted drugs) or immunotherapy in the past 3 months
- You must agree to effective birth control for 4 months after your last dose and cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.